Accrued Expense	3 Months Ended
Mar. 31, 2021
Accrued Expense
Accrued Expense	6. Accrued Expense As of March 31, 2021, current liabilities included accrued expenses of $1.0 million, comprised primarily of accrued employee vacation and bonus expenses of $0.5 million, expenses related to the Company’s clinical trial for prexigebersen in AML of $0.3 million, legal and patent fees of $0.1 million and other accrued expenses of $0.1 million. As of December 31, 2020, current liabilities included accrued expenses of $1.0 million, comprised primarily of expenses related to the Company’s clinical trial for prexigebersen in AML of $0.4 million,accrued employee vacation and bonus expenses of $0.4 million, manufacturing expenses of $0.1 million and other accrued expenses of $0.1 million.

Accrued Expense

3 Months Ended

Mar. 31, 2021

6. Accrued Expense

As of March 31, 2021, current liabilities included accrued expenses of $1.0 million, comprised primarily of accrued employee vacation and bonus expenses of $0.5 million, expenses related to the Company’s clinical trial for prexigebersen in AML of $0.3 million, legal and patent fees of $0.1 million and other accrued expenses of $0.1 million. As of December 31, 2020, current liabilities included accrued expenses of $1.0 million, comprised primarily of expenses related to the Company’s clinical trial for prexigebersen in AML of $0.4 million,accrued employee vacation and bonus expenses of $0.4 million, manufacturing expenses of $0.1 million and other accrued expenses of $0.1 million.